Cargando…
Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
LESSONS LEARNED. First trial to report safety and activity of the microtubule inhibitor vinflunine plus the tyrosine kinase inhibitor sorafenib in post‐platinum metastatic urothelial cancer (mUC) patients. A recommended phase II dose was identified for the treatment combination of vinflunine plus so...
Autores principales: | Shah, Carl‐Henrik, Pappot, Helle, Agerbæk, Mads, Holmsten, Karin, Jäderling, Fredrik, Yachnin, Jeffrey, Grybäck, Per, von der Maase, Hans, Ullén, Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656519/ https://www.ncbi.nlm.nih.gov/pubmed/30552156 http://dx.doi.org/10.1634/theoncologist.2018-0795 |
Ejemplares similares
-
Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
por: Holmsten, Karin, et al.
Publicado: (2016) -
Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
por: Holmsten, Karin, et al.
Publicado: (2017) -
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Shahda, Safi, et al.
Publicado: (2016) -
A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma
por: Uldrick, Thomas S., et al.
Publicado: (2017) -
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20
por: Patt, Yehuda, et al.
Publicado: (2017)